about
Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C.Performance of liver stiffness measurements by transient elastography in chronic hepatitis.Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C.Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection.Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection.Spontaneous hepatitis C virus clearance in HIV-infected patients: new insights for improving management.Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?Transfusion-transmitted virus infection in HIV-1-seropositive patients.Distinct mutational drug resistance profiles of HIV-1 RNA in plasma and culture isolates of patients receiving antiretroviral therapy.Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitisImpact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomasCould Tenofovir Modify the Model End-Stage Liver Disease (MELD) Score in Patients With End-Stage Liver Disease Eligible for Liver Transplantation?Comments on the review ‘Care of patients with hepatitis C and HIV co-infection’ by Soriano et alQuantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapyPerformance of Real-Time Strain Elastography, Transient Elastography, and Aspartate-to-Platelet Ratio Index in the Assessment of Fibrosis in Chronic Hepatitis CSplenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report
P50
Q24804388-88FA8F11-E03B-4A04-9C6E-79F4B4409784Q30459104-62FAAEA2-EE43-4C87-99D9-2796BB284AC2Q36384127-D7B64FFC-3B2D-4E33-A77D-3C35F29A6E7EQ36456458-A29B0E76-4463-4994-A7A2-22819B1511E6Q37803467-F6A5050D-BFA4-4AF5-88A5-CE007C2B9347Q37974697-18118FA7-FB1D-4EA2-A80C-A6D0362ADC5FQ38924167-262130C6-33DD-451C-93FA-AC305853C40FQ41579087-C4C97886-1760-4143-9591-65F7FD4B78CEQ42981329-0973F3A5-71F8-47F0-81F1-DDC9ACD462D6Q43040362-FA8B5B6C-8740-4490-AD45-50491DB112A9Q45738833-7D3D3CE5-58F1-44EE-8129-AC0CBEE5F91DQ53974434-63842670-34EC-4422-B97E-9A7B6AA907CAQ57718861-1E73919D-307A-4CC7-9B2F-0712AC582577Q57718877-78D520FF-A523-4A25-BA80-FC13C56FD859Q57718891-18FC5644-670A-4421-8C6D-9359127E016CQ57718920-1F6132B2-D529-4C39-B3CB-43C571E5C765Q57718964-8215A917-C0F1-4389-AAE8-A61183A5DF71Q57818212-931CC100-AFC1-4EC7-A9C3-1A079A3526CEQ81795291-6D36BC96-65B5-4231-9466-15C1514B046E
P50
description
researcher, ORCID id # 0000-0002-9679-0419
@en
wetenschapper
@nl
name
Paolo Sacchi
@ast
Paolo Sacchi
@en
Paolo Sacchi
@es
Paolo Sacchi
@nl
type
label
Paolo Sacchi
@ast
Paolo Sacchi
@en
Paolo Sacchi
@es
Paolo Sacchi
@nl
prefLabel
Paolo Sacchi
@ast
Paolo Sacchi
@en
Paolo Sacchi
@es
Paolo Sacchi
@nl
P106
P1153
7003763215
P31
P496
0000-0002-9679-0419